TCT In Brief
This article was originally published in The Gray Sheet
Executive Summary
Abbott bioabsorbable stent 30-day success rate is 94%: Everolimus-eluting, bioabsorbable BVS coronary stent achieves 93.5% delivery success rate with no major adverse cardiac events or stent thrombosis at 30-day follow-up. Results of Abbott's ABSORB trial, for BVS use in single, de novo, native coronary vessels, were presented Oct. 24 at the Transcatheter Cardiovascular Therapeutics conference in Washington, D.C., by principal investigator John Ormiston, MD, Auckland City Hospital, New Zealand. The stent demonstrated 7% recoil - "very similar to the recoil of a metallic stent," Ormiston said. Raimund Erbel, MD, University Duisburg-Essen, Germany, cautioned that the durability of polymer stent radial strength remains a concern because the polymers degrade over time (1"The Gray Sheet" April 10, 2006, p. 16)...
You may also be interested in...
Abbott’s SPIRITs Are Raised By Positive Drug-Eluting Stent Data At ACC
Abbott's SPIRIT III trial for its Xience V everolimus-eluting stent bodes well for the device's market potential and points to a new direction for stent manufacturers' premarket relationship with FDA
Abbott’s SPIRITs Are Raised By Positive Drug-Eluting Stent Data At ACC
Abbott's SPIRIT III trial for its Xience V everolimus-eluting stent bodes well for the device's market potential and points to a new direction for stent manufacturers' premarket relationship with FDA
Carotid Stent Firms See Another Step Into Market With Expanded Coverage
Carotid artery stent manufacturers hope to maintain momentum in an evolving market in which they see significant potential for growth